Login to Your Account



ODAC recommends go-slow approach for olaparib approval

By Mari Serebrov
Washington Editor

Wednesday, June 25, 2014
If the FDA follows the advice of its Oncologic Drugs Advisory Committee (ODAC), it will not be approving Astrazeneca plc's olaparib anytime soon as a maintenance therapy for BRCA-mutated ovarian cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription